4G/5G polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene in subjects with node-negative and node-positive breast cancer
Beata Smolarz, Janusz Błasiak, Jacek Pytel, Hanna Romanowicz-Makowska, Marek ZadrożnyMed Sci Monit 1999; 5(5): BR833-837 :: ID: 503262
Abstract
PAI-1 is a serine protease inhibitor involved in the degradation of the extracellular matrix during malignant tumor invasion and its high level in breast cancer is associated with a poor prognosis for patients. It is supposed that 4G/5G insertion/deletion polymorphism, with a sequence of either four guanosines or five guanosines, in the promoter of the PAI-1 gene may play a functional role in PAI-1 synthesis, affecting the level of circulating PAI-1. To investigate whether the progression of breast cancer may be related to a particular genotype, 4G/5G polymorphism in patients with node-negative (n=17) and node-positive (n=20) breast cancer was studied. The subjects were 44 to 82 years old, with a median age of 59 years. Formalin-fixed, paraffin-embedded material from ductal breast carcinoma was used. The tumors' diameter was about 20 mm and they were classified of II, II°, III or III°grade. The 4G/5G polymorphism of PAI-1 gene was determined by the allele specific polymerase chain reaction (ASO-PCR). The genotype distribution differed significantly between node-negative and node-positive groups. The 4G allele was observed more frequently in node-negative patients (0.74) compared with 5G allele (0.26), whereas in subjects with node-positive the frequency 4G and 5G allele were 0.48 and 0.52, respectively. Different distribution of the 4G/5G genotypes in patients indicate that this genetic variation itself may be a risk factor for breast cancer invasive phenotype, so the association of the 4G/5G polymorphism with breast cancer progression is worth further studying.
Keywords: PAI-1 - plasminogen activator inhibitor-1, 4G/5G polymorphism, prognostic factor, node-negative and node-positive breast cancer, allele specific polymerase chain reaction (ASO-PCR)
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952